Scholars Central

CommentaryPublished 15 Jul 2016

Imaging in diabetes

Authors: A Moore

Imaging in Medicine

Volume 1 · Issue 1 · Pages 23

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Dr Anna Moore graduated from the Moscow State University (Moscow Russia) and holds a PhD in bioorganic chemistry from the Russian Academy of Sciences. She moved to the USA in 1990 and joined a Molecular Imaging Program at Massachusetts General Hospital/Harvard Medical School (MA, USA) in 1991, first as a postdoctoral fellow and then as a junior faculty member. Currently, she is an Associate Professor in Radiology and a Director of the Molecular Imaging Laboratory at the Martinos Center for Biomedical Imaging (MA, USA). Dr Moore is a member of the Affiliated Faculty of the Harvard-MIT Division of Health Sciences and Technology. Her research deals with noninvasive imaging of molecular targets in cancer, diabetes and neurological disorders. Dr Moore is a recipient of multiple grant awards from the NIH and other agencies, and her research has been published in high-impact journals including Nature Medicine, Cancer Research, Diabetes, Radiology and others. You gained your PhD in Bioorganic Chemistry from the Russian Academy of Sciences & came to MGH in 1991. What led you to research diabetes at MGH? This is a complicated question to answer as there was no imaging in diabetes back then. The reason I came to the MGH, or to the USA in general, was because there was no funding for science in the former Soviet Union, and I could not work there because there was simply no money. So in 1990 I moved to the USA to work as a scientist, and in 1991 I joined MGH. When did you carry out your first work on diabetes? The first work on diabetes was around 1998; before that I was studying imaging in cancer and it just so happened that the diabetes community was looking for new methods to assess diabetes and to find a tool for monitoring treatment of early diabetes, in which there were no tools at the time. We knew how to use imaging in cancer so we basically applied a similar concept to imaging in diabetes. Currently how many people are working on this at the Athinoula A Martinos Center for Biomedical Imaging, Harvard & MGH? In my lab there is approximately 15 people and we have several different projects. Imaging in diabetes is just one direction of my lab – we also continue to work on imaging in cancer. I collaborate with many people at the Martinos Center, Harvard and the broader Boston scientific community, and also within the USA and in other countries. What did you find from your early studies in animals? Taking into account that there were no studies on imaging in diabetes at the time, we were learning what the diabetes communities needed the most and what we could give them that they did not have. It emerged that there was a whole spectrum of different problems they had that could be answered by noninvasive imaging. One of the problems was noninvasive evaluation of functional β-cell mass. This was probably the most important thing for the diabetes researchers.

Read the full text

Similar by topic

More from this journal

The newest in Imaging in Medicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalImaging in Medicine
  • SubjectRadiology & Imaging
  • BylineArticles whose byline prints “A Moore”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels